Biomarkers /
BCL2
Overview
B-cell CLL/lymphoma 2 (BCL2) is a gene that encodes a protein that functions as an integral outer mitochondrial membrane protein. The protein inhibits the apoptotic death of cell such as lymphocytes. Fusions, missense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as bone cancer, hematopoietic and lymphoid cancer, and stomach cancer.
BCL2 is altered in 0.97% of all cancers with follicular lymphoma, diffuse large B-cell lymphoma, not otherwise specified, colon adenocarcinoma, lung adenocarcinoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations [3].
The most common alterations in BCL2 are BCL2 Mutation (0.57%), BCL2 Loss (0.26%), BCL2 Amplification (0.13%), BCL2 Fusion (0.11%), and BCL2-IGH Fusion (0.23%) [3].
Biomarker-Directed Therapies
Clinical Trials
Significance of BCL2 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.